نتایج جستجو برای: adjuvant candidate

تعداد نتایج: 155644  

Journal: :iranian journal of parasitology 0
majid pirestani dept. of parasitology and medical entomology, faculty of medical sciences, tarbiat modares university, tehran, iran. abdolhossein dalimi dept. of parasitology and medical entomology, faculty of medical sciences, tarbiat modares university, tehran, iran. shahabodin sarvi dept. of parasitology and mycology, sari medical school, mazandaran university of medical sciences, sari, iran. nima khoramabadi dept. of medical microbiology, faculty of medical sciences, tarbiat modares university, tehran, iran.

background: echinococcosis is a zoonotic parasitic disease of humans and various herbivorous domestic animals transmitted by the contact with domestic and wild carnivores,mainly dogs and foxes. the aim of this study is the production, purification and evaluation immunogenicity of new construction of eg95 protein. methods: the recombinant plasmid pet32-a+ used for eg95 expression was constructed...

Hamid Madanchi Hossein Honari, Mahdi Hesaraki Mohammad Sadraeian

       Cholera toxin B subunit (CtxB) is a homopantameric, nontoxic subunit of cholera toxin that is responsible for its binding to the cell and has been known as a mucosal adjuvant for vaccines that could increase homoral and mocusal immunity response. In this work, the CtxB gene was fused to the StxB gene from Shigella dysenteriae type I a vaccine antigen candidate against t...

Journal: :iranian journal of pharmaceutical sciences 0
hamid madanchi department of biology, imam houssein university, tehran, iran hossein honari department of biology, imam houssein university, tehran, iran mohammad sadraeian department of biology, imam houssein university, tehran, iran mahdi hesaraki department of biology, imam houssein university, tehran, iran

cholera toxin b subunit (ctxb) is a homopantameric, nontoxic subunit of cholera toxin that is responsible for its binding to the cell and has been known as a mucosal adjuvant for vaccines that could increase homoral and mocusal immunity response. in this work, the ctxb gene was fused to the stxb gene from shigella dysenteriae type i a vaccine antigen candidate against this pathogen, by a nonfur...

Journal: :journal of medical microbiology and infectious diseases 0
faramarz dobakhti school of pharmacy, zanjan university of medical sciences, zanjan, iran ghader khalili immunology department, pasteur institute of iran, tehran, iran hamid mahmoudzadeh niknam immunology department, pasteur institute of iran, tehran, iran vahid khaze immunology department, pasteur institute of iran, tehran, iran fatemeh partovi faculty of public health, shahid beheshti university of medical sciences, tehran, iran taraneh naghibi mahmoodabadi school of medicine, zanjan university of medical sciences, zanjan, iran

various adjuvants in combination with different antigens have been utilized as a vaccine candidate against leishmaniasis. however, the search for ideal adjuvants is still pursued due to the inefficiencies of current compounds. in the present study, the effect of imiquimod, as an adjuvant, is studied with soluble leishmania antigens (sla) in balb/c mice. four groups of mice were immunized with s...

2018
Jemal Hussein Martha Zewdie Lawrence Yamuah Ahmed Bedru Markos Abebe Alemnew F Dagnew Menberework Chanyalew Asfawesen G Yohannes Jemal Ahmed Howard Engers T Mark Doherty Peter Bang Ingrid Kromann Søren T Hoff Abraham Aseffa

BACKGROUND H1/IC31® is a tuberculosis (TB) subunit vaccine candidate consisting of the fusion protein of Ag85B and ESAT-6 (H1) formulated with the IC31® adjuvant. Previous trials have reported on the H1/IC31® vaccine in M. tuberculosis (Mtb)-naïve, BCG-vaccinated and previously Mtb-infected individuals. In this trial, conducted between December 2008 and April 2010, the safety and immunogenicity...

Journal: :Journal of virology 1998
M Ciarlet S E Crawford C Barone A Bertolotti-Ciarlet R F Ramig M K Estes M E Conner

Virus-like particles (VLPs) are being evaluated as a candidate rotavirus vaccine. The immunogenicity and protective efficacy of different formulations of VLPs administered parenterally to rabbits were tested. Two doses of VLPs (2/6-, G3 2/6/7-, or P[2], G3 2/4/6/7-VLPs) or SA11 simian rotavirus in Freund's adjuvants, QS-21 (saponin adjuvant), or aluminum phosphate (AlP) were administered. Serol...

2012
Emily K. Forbes Simone C. de Cassan David Llewellyn Sumi Biswas Anna L. Goodman Matthew G. Cottingham Carole A. Long Richard J. Pleass Adrian V. S. Hill Fergal Hill Simon J. Draper

Viral vectored vaccines have been shown to induce both T cell and antibody responses in animals and humans. However, the induction of even higher level T cell responses may be crucial in achieving vaccine efficacy against difficult disease targets, especially in humans. Here we investigate the oligomerization domain of the α-chain of C4b-binding protein (C4 bp) as a candidate T cell "molecular ...

Journal: :Clinical and vaccine immunology : CVI 2008
Damiana Chiavolini Susan Weir John R Murphy Lee M Wetzler

Francisella tularensis causes severe pneumonia that can be fatal if it is left untreated. Due to its potential use as a biological weapon, research is being conducted to develop an effective vaccine and to select and study adjuvant molecules able to generate a better and long-lasting protective effect. PorB, a porin from Neisseria meningitidis, is a well-established Toll-like receptor 2 ligand ...

Journal: :Vaccine 2017
Maria Norrby Timo Vesikari Lars Lindqvist Markus Maeurer Raija Ahmed Shahnaz Mahdavifar Sean Bennett J Bruce McClain Barbara M Shepherd Daner Li David A Hokey Ingrid Kromann Søren T Hoff Peter Andersen Adriëtte W de Visser Simone A Joosten Tom H M Ottenhoff Jan Andersson Susanna Brighenti

BACKGROUND Novel vaccine strategies are required to provide protective immunity in tuberculosis (TB) and prevent development of active disease. We investigated the safety and immunogenicity of a novel TB vaccine candidate, H4:IC31 (AERAS-404) that is composed of a fusion protein of M. tuberculosis antigens Ag85B and TB10.4 combined with an IC31® adjuvant. METHODS BCG-vaccinated healthy subjec...

Journal: :nanomedicine journal 0
seyedeh mahnaz karimi school of pharmacy, mashhad university of medical sciences, mashhad, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (mashhad university of medical sciences) mojtaba sankian faculty of medicine and immunology research center, mashhad university of medical sciences, mashhad, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (mashhad university of medical sciences) farzad khademi antimicrobial resistance research center, department of medical bacteriology and virology, qaem university hospital, school of medicine, mashhad university of medical sciences, mashhad, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (mashhad university of medical sciences) mohsen tafaghodi nanotechnology research center, mashhad university of medical sciences, mashhad, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (mashhad university of medical sciences)

objective(s): an efficient vaccine against tb is an urgent need. tb peptides are safe candidate but they are weak immunogens and needs to be potentiated by adjuvant/delivery systems. the main purpose of the present study was to determine the potential of cht based nps containing esat-6 antigen of m. tuberculosis for inducing mucosal and systemic immune responses after intranasal and subcutaneou...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید